6.73
-0.06 (-0.88%)
| Previous Close | 6.79 |
| Open | 6.68 |
| Volume | 1,009,448 |
| Avg. Volume (3M) | 1,223,138 |
| Market Cap | 1,032,960,768 |
| Price / Sales | 7.56 |
| Price / Book | 4.34 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2025 - 12 May 2025 |
| Profit Margin | -89.57% |
| Operating Margin (TTM) | 27.42% |
| Diluted EPS (TTM) | -0.700 |
| Quarterly Revenue Growth (YOY) | 188.20% |
| Total Debt/Equity (MRQ) | 11.69% |
| Current Ratio (MRQ) | 2.89 |
| Operating Cash Flow (TTM) | -151.03 M |
| Levered Free Cash Flow (TTM) | -107.84 M |
| Return on Assets (TTM) | -22.00% |
| Return on Equity (TTM) | -73.24% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Wave Life Sciences Ltd. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | -4.0 |
| Average | 0.75 |
|
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington’s disease. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 16.53% |
| % Held by Institutions | 83.46% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| M28 Capital Management Lp | 31 Dec 2024 | 5,664,548 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 26.00 (Jefferies, 286.33%) | Buy |
| Median | 22.00 (226.90%) | |
| Low | 10.00 (Cantor Fitzgerald, 48.59%) | Buy |
| Average | 19.33 (187.22%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 9.04 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Cantor Fitzgerald | 29 Apr 2025 | 10.00 (48.59%) | Buy | 6.73 |
| HC Wainwright & Co. | 26 Mar 2025 | 22.00 (226.89%) | Buy | 10.02 |
| 05 Mar 2025 | 22.00 (226.89%) | Buy | 10.57 | |
| Jefferies | 25 Feb 2025 | 26.00 (286.33%) | Buy | 10.36 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 01 May 2025 | Announcement | Wave Life Sciences First Quarter 2025 Financial Results Scheduled for May 8, 2025 |
| 26 Mar 2025 | Announcement | Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531 |
| 04 Mar 2025 | Announcement | Wave Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update |
| 25 Feb 2025 | Announcement | Wave Life Sciences Fourth Quarter and Full Year 2024 Financial Results Scheduled for March 4, 2025 |
| 06 Feb 2025 | Announcement | Wave Life Sciences Announces Initiation of Phase 1 INLIGHT Clinical Trial of WVE-007 in Obesity |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |